rationale – Page 19 – Communicable Diseases Research

The Rationale for Potential Pharmacotherapy of COVID-19

Review

Published on 2020-05-142022-10-28
Journal: Pharmaceuticals
[Category] COVID-19,

SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment

Review

Published on 2020-05-102022-10-29
Journal: International Journal of Molecular Sciences
[Category] COVID-19, MERS, SARS,

Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids

Article

Published on 2020-05-082022-10-04
Journal: International immunopharmacology
[Category] MERS, SARS, 임상, 치료법,

[키워드] accelerate anti-IL6 antibody benefit cell entry Characteristics clinical benefit Controlled clinical trial correlated Corticosteroid Corticosteroids COVID-19 COVID-19-related death cytokine essential element fatal disease humans Hypothesis IL6 immune system Immunoglobulin immunoglobulins immunosuppressive IMPROVE Inflammation interleukin 6 monoclonal antibody Novel coronavirus outcomes Patient patients with COVID-19 pro-inflammatory cytokine Prognosis prognosis of patient rationale reduce SARS-CoV2 severe COVID-19 severity shown target targeted therapy therapeutic option therapy Treatment use of corticosteroid Viral load with COVID-19
[DOI] 10.1016/j.intimp.2020.106560 PMC 바로가기 [Article Type] Article

CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients

Research Paper

Published on 2020-04-272022-10-28
Journal: Theranostics
[Category] COVID-19, MERS, SARS,

[키워드] 95% CI 95% confidence interval adjusted age and gender Algorithms artificial intelligence automatically calculated change characteristic Chest CT Clinical management Cohort collected Computed tomography consolidation coronavirus disease COVID-19 COVID-19 patient COVID-19 patients develop elevated feature Features Follow-up ground-glass opacity hazard ratio Health Hospital admission Logistic regression Lungs Neutrophil-to-lymphocyte ratio NLR Occurrence Patient patients percentage performed pneumonia lesion predict Predictive prognostic indicator progression PSV quantification Quantitative rationale representing Respiratory failure Result retrospective cohort retrospective cohort study risk severe illness Volume
[DOI] 10.7150/thno.45985 PMC 바로가기 [Article Type] Research Paper

Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients

Research Paper

Published on 2020-04-272022-10-28
Journal: Theranostics
[Category] COVID-19, MERS, SARS,

[키워드] 95% confidence interval Admission age Analysis analyzed association Characteristics China clinical Clinical outcome cohort study composite endpoint Computed tomography consolidation coronavirus disease COVID-19 COVID-19 patient COVID-19 pneumonia CT finding CT scan endpoints enrolled follow-up period GGO ground-glass opacity higher odd hospital Hospitalization ICU identify increase initial Jiangsu laboratory-confirmed lesion lesions logistic regression model lung male median age medical records Occurrence Odds ratio Older age outcome parameter Patient patients with COVID-19 Pneumonia proportion rationale Respiratory failure Result retrospective cohort study risk risk factor Shock Volume were excluded were used
[DOI] 10.7150/thno.46465 PMC 바로가기 [Article Type] Research Paper

Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

Infectious Disease

Published on 2020-03-202022-10-31
Journal: Cureus
[Category] COVID-19,

[키워드] acetazolamide Activation acute respiratory distress addition Anti-viral appear approach ARDS asymmetric caused change Clinical data Coagulation condition Contagion coronavirus countermeasure COVID-19 COVID-2019 CT finding Diffuse alveolar damage edema Effect effective elevated expired fatality fibrinogen level ground glass opacities Ground glass opacity ground-glass opacity Hemorrhagic high altitude pulmonary edema hypoxia hypoxic IMPROVE include increase in indication induce inhibitors lung medication minute ventilation Nifedipine Novel coronavirus organ systems oxygen patchy pathophysiologic pathophysiology patients with COVID-19 Perspective phosphodiesterase pro-inflammatory Pulmonary edema rationale reduce Respiratory care Respiratory illness respiratory parameter shown similarity survival syndrome tachypnea Treatment utilization vasoconstriction while Wuhan coronavirus
[DOI] 10.7759/cureus.7343 PMC 바로가기 [Article Type] Infectious Disease

Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled” trial (TOCIBRAS)

"중등도에서 중증의 COVID-19 환자에 대한 토실리주맙: 공개 라벨 다기관 무작위 통제" 시험(TOCIBRAS)의 근거 및 설계

Original Article

Published on 2020-01-012022-08-13
Journal: Revista Brasileira de Terapia Intensiva
[Category] 임상,

[키워드] 7-point ordinal scale adjusted age and sex alleviate Analysis anti-inflammatory therapies Anti-inflammatory therapy applied approved Brazil C reactive protein Clinical outcome clinical outcomes clinical status combating consequence Coronavírus COVID-19 COVID-19 patient COVID-19 patients criteria D-dimer disease severity dissemination enrolment ethical committee Ethics ferritin IMPROVE inflammatory cascade inflammatory mediator Inflammatory response inhibiting institutional review board institutional review boards interleukin-6 International Lactate lactate dehydrogenase limit Local mediator moderate to severe multicentre National Odds ratio Open-label ordinal logistic regression Ordinal Scale outcome patients patients with COVID-19 patients with moderate primary endpoint Pro-inflammatory marker pro-inflammatory markers protocol Randomized Randomized controlled trial rationale required severe COVID-19 severity Standard of care Stratification Study protocol the disease The TOCIBRAS protocol TOCIBRAS Tocilizumab Tocilizumabe Trial trial testing variable
[DOI] 10.5935/0103-507X.20200060 PMC 바로가기 [Article Type] Original Article

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Review

Published on 2019-04-242023-08-30
Journal: Journal of Hematology & Oncology
[Category] E형 간염,

[키워드] Clinical application clinical trial Combination immunotherapy Gastrointestinal malignancies Immune checkpoint inhibitor PD-1/PD-L1 blockade rationale
[DOI] 10.1186/s13045-019-0730-9 PMC 바로가기 [Article Type] Review

Epistatic control of intrinsic resistance by virulence genes in Listeria

리스테리아의 병독성 유전자에 의한 내인성 내성의 상위성 조절

Research Article

Published on 2018-09-042022-09-06
Journal: PLoS Genetics
[Category] Communicable Disease,

[키워드] activated Activation addition antibiotic antimicrobial resistance antimicrobial susceptibility Bacteria Bacterial bacterial cell complex conditions core genome determinant dissect drug drug-resistant Effect enzyme epistasis Evidence Evolution evolutionary dynamics fosfomycin functional Genes genomic gram gram-positive bacterium Host in vitro induce Infection Infectious disease Interaction intrinsic intrinsically isolate L . monocytogene Listeria Listeria monocytogene Listeria monocytogenes listeriosis loci locus mechanism microbe molecular molecular basis organism pathogen pathogenic Pathogens phenomenon phenotype phenotypic effect Population dynamics prfA PROTECT provide rationale reported resistance gene resistance genes Strains suppressed susceptibility susceptible traits treat Treatment understanding virulence virulence gene virulence genes virulent working
[DOI] 10.1371/journal.pgen.1007525 PMC 바로가기 [Article Type] Research Article